3 Kapital suchende Unternehmen Unternehmensprofile - Deutsches ...

Medicyte GmbH
Biotechnologie
Profil
Jahr der Gründung
Mitarbeiter
Eigenkapital (in m EUR)
Kapital Bedarf (in m EUR)
Positives Ergebnis seit
Umsatz 2009 (in m EUR)
Umsatz 2010e (in m EUR)
Umsatz 2011e (in m EUR)
Kontakt
Ansprechpartner
Telefon
Fax
E-Mail
Web
Adresse
2007
9
1.8
4.6
2013
k.A.
0.5
Dipl. Oec. Stefan Holder
+49-(0) 62 21-7 29 25-30
+49-(0) 62 21-7 29 25-31
2
s.holder@medicyte.com
www.medicyte.com
Im Neuenheimer Feld 581
69120 Heidelberg
Deutschland
3 / 30
Geschäftsfeld
Medicyte is a life science company specialised in the controlled,
scalable generation and standardisation of human primary cell
products. Medicyte's technologies enable expansion of primary
cells providing large quantities and consistent quality currently
not commercially available. With the innovative product families
upcyte® and vericyte® Medicyte is addressing the growing markets
of cell-based R&D and cell therapy with high unmet needs
for the supply of healthy human primary cells, novel cell-based
research tools and therapeutic cell products.
Strategische Marktposition
The vision is to establish Medicyte’s proprietary technology as
a gold standard and preferred source of human primary cell
products for research, industrial and therapeutic applications.
Medicyte’s products combine superior quality with industrial
scalability. The company is targeting the fast growing markets for
cells and cell systems as well as the emerging multi-billion Euro
market for regenerative medicine. In 2010 Medicyte will grow its
revenues significantly from sales of novel high end primary cell
products as well as from licensing technologies and products for
non therapeutic applications.
Management
The Company is lead by a team with >60 years of relevant management
and product development experience in life sciences.
Managing Directors are Stefan Holder and Dr. Joris Braspenning.
Beabsichtigte Investition/Zusätzliche Informationen
In a Series B financing round Medicyte intends to raise a singledigit
million € amount to continue the development of the technology
platform, extend the validation through further commercial
partnering, launch additional market entries and prepare the
path to clinical applications.
Medicyte has previously secured Series A funding from the Prinz
von Hohenzollern Capital, the KfW, Dr. Björn F. Lindemann and
from state grants.